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Abstract
Background: Thrombin activates hepatic stellate cells via protease-activated receptor-1. The role of Factor Xa (FXa)
in hepatic fibrosis has not been elucidated. We aimed to evaluate the impact of FXa and thrombin in vitro on stellate
cells and their respective inhibition in vivo using a rodent model of hepatic fibrosis.
Methods: HSC-LX2 cells were incubated with FXa and/or thrombin in cell culture, stained for αSMA and relative gene
expression and gel contraction calculated. C57BL/6 J mice were administered thioacetamide (TAA) for 8 weeks with
Rivaroxaban (n= 15) or Dabigatran (n = 15). Control animals received TAA alone (n = 15). Fibrosis was scored and quantified
using digital image analysis and hepatic tissue hydroxyproline estimated.
Results: Stellate cells treated with FXa and thrombin demonstrated upregulation of procollagen, TGF-beta, αSMA and
significant cell contraction (43.48%+/− 4.12) compared to culturing with FXa or thrombin alone (26.90%+/− 8.90, p= 0.02;
13.1%+/− 9.84, p< 0.001). Mean fibrosis score, percentage area of fibrosis and hepatic hydroxyproline content (2.46 vs 4.08,
p= 0.008; 2.02% vs 3.76%, p= 0.012; 276.0 vs 651.3, p= 0.0001) were significantly reduced in mice treated with the FXa
inhibitor compared to control mice. FXa inhibition was significantly more effective than thrombin inhibition in reducing
percentage area of fibrosis and hepatic hydroxyproline content (2.02% vs 3.70%,p= 0.031; 276.0 vs 413.1,p= 0.001).
Conclusions: FXa promotes stellate cell contractility and activation. Early inhibition of coagulation using a FXa
inhibitor significantly reduces TAA induced murine liver fibrosis and may be a viable treatment for liver fibrosis
in patients.
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Background
The interaction between the coagulation cascade and
liver injury is multifaceted [1]. Although prolongation of
the prothrombin time is a well-recognized consequence
of chronic liver disease, recent studies demonstrate that
patients with advanced fibrosis can also have reduced
levels of protein C and antithrombin, balancing any re-
duction in thrombin generation [2, 3]. This may in part
explain the paradoxical increased relative risk of venous
thromboembolic disease observed in patients with
chronic liver disease in a recent large case-control popu-
lation based study [4].
Evidence now suggests a role for coagulation proteins in
the pathogenesis of liver fibrosis [5]. Firstly, epidemio-
logical studies have demonstrated that prothrombotic
conditions promote liver fibrosis [6–9]. Secondly, Tissue
Factor and fibrin have been shown to be upregulated
within fibrotic livers, which is in keeping with a role for
vascular dysfunction in fibrogenesis [10–13]. Thirdly, in
addition to its role in activating fibrinogen, thrombin has
been shown to mediate the cellular activation of macro-
phages, platelets and hepatic stellate cells (HSCs) via
cleavage of the protease-activated receptor, PAR-1 [14, 15]
and polymorphisms in the PAR-1 gene have been shown
to influence rates of hepatic fibrosis [16]. Finally, warfarin
and experimental thrombin antagonists have demon-
strated some anti-fibrotic properties in animal models of
liver fibrosis [17, 18]. Recently FXa, a protease activated
upstream of thrombin in the coagulation cascade, has
been shown to promote fibrogenesis via direct PAR recep-
tor cleavage in pulmonary fibrosis [19, 20]. Activation of
FXa may therefore drive hepatic fibrogenesis both through
direct PAR activation and by thrombin generation, making
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it an attractive therapeutic target. To date no study has ex-
amined the direct effects of FXa on HSC activity. In lung
fibrosis, which is biologically analogous to hepatic fibrosis,
treatment with a direct inhibitor of FXa reduces fibrosis
significantly in a murine bleomycin-inhalation model [20].
An understanding of the effect of FXa on HSCs and fibro-
genesis, above and beyond its role in generating thrombin
is therefore needed, and the effects of direct FXa inhib-
ition in the setting of hepatic fibrosis need to be evaluated
to assess whether it could offer additional efficacy over
direct thrombin inhibition as an anti-fibrotic agent.
Using the human LX2 hepatic stellate cell culture line
we sought to determine the relative efficacy of FXa and
thrombin on HSC activity in vitro. We then evaluated
the anti-fibrotic potential in vivo of both direct FXa
inhibition with Rivaroxaban (Bayer Healthcare,
Germany) and direct thrombin inhibition with
Dabigatran, (Boehringer Ingelheim Pharma, Germany)
using a murine model of liver fibrosis.
Methods
In vitro studies
HSC LX2 cell culture
LX-2 cells are a commonly used hepatic stellate cell
(HSC) line [21] and were kindly provided by S Friedman
(Mount Sinai, New York, New York). Cells were main-
tained in DMEM (ThermoFisher, UK) supplemented with
10% FBS and 2 mM L-Glutamine. For experimental pro-
cedures, cells were incubated for 24 h in a humidified en-
vironment of 5% CO2 with serum free media alone
(control) or serum free media supplemented with 0.5 U/
ml FXa (Enzyme Research Lab, USA); 10 nM thrombin
(Sigma, UK); or 0.5 U/ml FXa and 10 nM thrombin. FXa
at 0.5 – 1 U/ml has been previously used in other studies
[22]. After incubation the media was gently removed and
cells were fixed by pipetting paraformaldehyde into each
well and incubating at room temperature. Cells were im-
munostained for αSMA, a marker of HSC activation,
using a mouse monoclonal antibody raised against alpha-
smooth muscle actin (Clone 1A4, Dako Inc., USA). For
gene expression studies, total RNA was isolated from cells
stimulated with FXa and/ or Thrombin (RNeasy Mini kit,
Qiagen Ltd., Crawley, UK), reverse transcribed (RETRO-
script kit; Thermofisher, UK) and quantitative polymerase
chain reaction (qPCR) analysis was performed using
TaqMan Gene Expression Assays (ThermoFisher, UK).
Data were normalized to the endogenous housekeeping
gene GADPH and fold change differences in expression
relative to control (untreated LX2) cells were calculated
using the Comparative ddCT method [17, 23].
HSC gel contractility assay
HSC contractility assays were performed as previously
described with some minor modifications [24]. LX-2
cells were layered on top of the collagen lattice in 24
well plates and serum starved for 24 h. Gel contraction
was induced by incubation of duplicate wells with 10%
FBS, which acted as the positive control, or the proposed
agonists, FXa or thrombin in the following combina-
tions: 0.5 U/ml FXa alone; 10 nM thrombin alone; or 0.
5 U/ml FXa with 10 nM thrombin. Additional wells con-
taining a cell free lattice and wells containing a lattice
with LX2 cells without any agonist, acted as controls for
spontaneous gel shrinkage. Gels were released from wall
using a micro-pipetting tip (representing time point
zero) and photographed at 6 h. Surface area of the colla-
gen gels was measured using digital image analysis soft-
ware, and images were processed using digital image
analysis. Relative contraction of the gels was expressed
as a percentage of the surface area contraction of each
experimental gel in comparison to gels incubated with
media and LX2 cells alone.
Animals studies
All research using live animals was approved by the local
ethics committee and carried out in accordance with the
Animal (Scientific Procedures) Act 1986. Institutional
guidelines were followed for the care and use of animals.
Forty five male C57BL/6 J mice, aged 8 weeks old, were
purchased from Jackson Laboratories (USA). All mice
were housed under standard conditions and treated with
TAA to induce liver fibrosis for 8 weeks via drinking
water at a dose of 300 mg/l. Animals were randomly al-
located to treatment or control groups. Rivaroxaban and
Dabigatran were acquired from commercial source.
Tablets were crushed and dissolved in water to achieve
fine suspension. Two subgroups (n = 15 each) were
treated, once daily, by oral gavage with either Rivaroxa-
ban, (FXa inhibitor group) at a dose of 40 mg/kg or
Dabigatran (thrombin antagonist group) at a dose of
100 mg/kg. Control group mice (n = 15) received no
anticoagulation. Doses of anticoagulants were attained
to cause equivalent prolongation of coagulation times,
including the International Normalised Ratio (INR) to
between 1.5 to 2, as measured using a handheld coagula-
tion meter, following blood sampling from animals tail
veins and referencing previous dosing and rodent data
[25–27]. Gavage volumes were administered based on
each individual animal as per a pre-formulated weight/
dose chart. At 8 weeks, all surviving animals from each
experimental group were culled by intraperitoneal injec-
tion of 0.1 ml Pentoject (Pentobarbitone Sodium Ph.Eur.
200 mg/ml, Animal Care Ltd., UK) followed by cervical
dislocation and livers harvested.
Histopathology and digital image analysis
Liver tissue from each animal was fixed in 10% formalin,
processed into paraffin wax and sections stained with
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Haemotoxylin & Eosin (H&E) and Picro-Sirius red, a com-
monly used stain for collagen and fibrosis [28]. All sec-
tions were examined using a light microscope by a
histopathologist blinded to the therapy received. The ex-
tent of hepatic fibrosis was assessed using a semi-
quantitative score in a manner previously described in
mouse models of fibrosis [17] and digital image analysis to
calculate mean percentage area of fibrosis. Tissue was
stained for αSMA, as described above and examined with
a light microscope to calculate the mean number of acti-
vated stellate cells for each individual animal per field.
Tissue hydroxyproline measurement
Hydroxyproline content has been described as a surro-
gate for collagen content in fibrogenesis [29] and was
measured using a commercially available kit (BioVision
K555-100, USA). Briefly, pre-weighed frozen liver tissue
samples were homogenised in water and hydrolysed in
12 N HCl at 120 °C for 3 h, and 10μl of the hydrolysate
was evaporated to dryness under vacuum. Chloramine T
(100μl) was added and incubated for 5 min at room
temperature. Then 100μl of DMAB (4-(dimethylamino)
benzaldehyde) reagent was pipetted into each sample
and incubated for 90 min at 60 °C. Absorbance was read
at 560 nm and total hydroxyproline content in the sam-
ples was extrapolated from the standard curve.
Statistical analysis
Statistical analysis was performed using SPSS v16 (SPSS,
USA). Normally distributed continuous variables were
compared by Student’s t-test. Variables which were not
distributed normally were compared using the non-
parametric tests, Mann-Whitney or Kruskall-Wallis.
Quantitative data were expressed as mean +/− standard
error of mean (SEM), unless otherwise stated. Statistical
significance was accepted at p < 0.05.
Results
In vitro studies
LX2 hepatic stellate cell line
To determine the effect of individual coagulation pro-
teins on the activity of HSCs, the principal cell of hep-
atic fibrosis, LX2 cell lines were cultured. Expression of
αSMA and cell contraction was used as markers of stel-
late cell activation and is represented in Fig. 1. Incuba-
tion of LX2 cells with medium alone on a glass surface
resulting in minimal contraction and αSMA expression
(Fig. 1a&b). Incubation with thrombin demonstrated
weakly positive staining for αSMA in LX2 cells (see Fig.
1c&d). αSMA staining and cell contraction was more
prominent with when cells were incubated with FXa
(Fig. 1e&f). FXa and thrombin together resulted in heavy
staining for αSMA, with cell contraction more exagger-
ated than with thrombin alone (Fig. 1g&h). Relative gene
expression using qPCR demonstrated a significant in-
crease in the procollagen, and TGF expression when
LX2 cells incubated with both FXa and Thrombin, com-
pared to thrombin (p = 0.01; p = 0.01) or FXa (p = 0.01;
p = 0.02) alone (Fig. 1i&k). FXa and thrombin resulting
in a significant increase in αSMA gene expression com-
pared to thrombin alone (p = 0.04) (Fig. 1j). There was
no significant difference in procollagen, TGF-beta or
αSMA gene expression between cells incubated with
FXa or thrombin alone.
HSC contractility assay
The use of contractility gel assays allows for a quantitative
measurement of hepatic stellate cell contractility [24]. In-
cubation of LX2 cells with medium alone resulted in a
small degree of spontaneous gel shrinkage at 6 h (Fig. 2a),
and was used as a control. The mean surface area of ex-
perimental gels was expressed as a percentage of the sur-
face area of mean control gels and subtracted from 100 to
calculate the percentage gel contraction. This allowed for
any correction of spontaneous gel shrinkage that may have
occurred. Incubation with FBS, which is used as a positive
control in this type of assay, resulted in a significant con-
traction of gels, thus validating the technique. The
addition of FXa and thrombin individually resulted in con-
traction of gels. FXa treated gels demonstrated more con-
traction at 6 h, than those treated with thrombin (26.90%
+/− 8.90 versus 13.10% +/− 9.84), but the difference did
not reach significance (Fig. 2b, c & e). The addition of FXa
and thrombin together however demonstrated a potenti-
ated effect on cell contraction (43.48% +/− 4.12), with sig-
nificantly more contraction compared to incubation with
FXa (p = 0.02) or thrombin alone (p < 0.001) (Fig. 2d & e).
Animal studies
Early mortality affected both treatment and control sub-
groups equally. Two to three mice were lost from each
group due to procedural complications following gavage
during the course of the study, and none were related to
spontaneous hemorrhage. All animals were weighed
every second week. No animal recorded a reduction in
overall weight at the end of the study, in comparison to
its starting weight.
Fibrosis scoring and percentage area of fibrosis in TAA
treated mice
After 8 weeks of exposure with TAA via drinking water
(300 mg/L), control mice demonstrated bridging fibrosis
with occasional nodule formation (Fig. 3a). Mice treated
with the direct thrombin antagonist, Dabigatran
(100 mg/kg), exhibited frequent bridging fibrosis, similar
to control mice, but only occasional nodule formation
(Fig. 3b). In contrast, mice treated with the direct FXa
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inhibitor Rivaroxaban (40 mg/kg) demonstrated milder
fibrosis, with fibrous expansion around the central veins,
less frequent bridging and the absence of nodules (Fig.
3c). In keeping with this finding, mean fibrosis scores in
mice treated with Rivaroxaban were significantly re-
duced (p = 0.008) in comparison to control mice (2.46 ±
0.33 versus 3.76 ± 0.36) and there was a significant re-
duction (p = 0.012) in mean percentage area of fibrosis
(2.02% ± 0.39 versus 4.08 ± 0.66) (Fig. 4). In contrast,
mice treated with Dabigatran, had a mean fibrosis score
of 3.25 ± 0.63 (SEM) and mean percentage area of fibro-
sis of 3.70% ± 0.63 (SEM). This represented only a 13
and 9% reduction respectively compared to control mice
and did not reach statistical significance (Fig. 4). When
comparing direct FXa inhibition to direct thrombin an-
tagonism, FXa inhibition demonstrated a significant re-
duction in mean percentage area of fibrosis (p = 0.031)
(Fig. 4).
Alpha smooth muscle actin expression in TAA treated
mice
Following 8 weeks exposure to TAA, mice treated with
Rivaroxaban demonstrated a significant reduction in
the mean number of αSMA positive hepatic stellate
cells per field of view compared to control group mice
(5.23 ± 1.06 versus 10.62 ± 1.92; p = 0.02). Treatment
with Dabigatran however only resulted in a trend to-
wards decreased reduction in αSMA expression com-
pared to control mice (7.29 ± 1.39 versus 10.62 ± 1.92;
p > 0.05) (Figs. 3 and 4).
Hepatic hydroxyproline content in TAA treated mice
Mice treated with Rivaroxaban demonstrated a signifi-
cant reduction in the mean hepatic hydroxyproline con-
tent compared to control group mice (276.0 ± 30.2
versus 651.3 ± 46.7; p < 0.0001). Dabigatran (100 mg/kg)
Fig. 1 Effect of FXa, thrombin on LX2 cells in vitro. a & b Incubation of cells with control medium alone resulting in minimal cell contraction and
staining for αSMA (× 100 magnification). c & d Incubation of LX2 cells with thrombin at a dose of 10 nM resulted in some activation of LX2 cells
with positive staining for αSMA and some contraction (× 100 magnification) e & f Incubation of LX2 cells with FXa at a dose of 0.5 U/ml resulted
in activation of LX2 cells with positive staining for αSMA and a contracted phenotype (× 100 magnification). g & h Addition of FXa (0.5 U/ml) in
combination with thrombin (10 nM) resulted in activation of LX2 cells with heavy positive staining for αSMA and a contracted phenotype (× 100
magnification). i - k LX2 cells were incubated with FXa and/or thrombin. αSMA, procollagen and TGF-beta expression were analysed by qRT-PCR.
Data were normalized to the endogenous housekeeping gene GADPH and fold change differences in expression relative to control (untreated
LX2) cells were calculated using the Comparative ddCT method. Data are Mean ± SEM from one of the representative experiments. Significance
was denoted as *p < 0.05, **p < 0.01. Abbreviations: αSMA, alpha smooth muscle actin; FXa, Factor Xa; TGF-beta, Transforming growth factor beta;
Thr, Thrombin
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resulted in a significant reduction in the mean hepatic
hydroxyproline content compared to control group mice
(413.1 ± 1.39; p = 0.001). FXa inhibition was associated
with significantly lower hydroxyproline levels than that
observed with thrombin inhibition (p = 0.016) (Fig. 4).
Discussion
Recent evidence suggests hepatic fibrogenesis is associ-
ated with prothrombotic tendencies [3, 4, 6, 17] and co-
agulation proteins are up-regulated in fibrotic livers [10–
12]. The presence of activated coagulation proteins in
Fig. 3 Histological images using Picro-sirius red staining (a-c) of liver tissue for fibrosis and immunohistochemical staining for αSMA (d-f) in mice
treated with 8 weeks of thioacetamide (TAA) with or without FXa or thrombin inhibition. Control mice treated with TAA (n = 13) alone (A; ×
15magnification). Mice treated with TAA and the thrombin inhibitor (n = 12), Dabigatran (100 mg/kg) (B; × 15 magnification). Mice treated with
TAA and the FXa inhibitor (n = 13), Rivaroxaban (40 mg/kg) (C; × 15 magnification)
Fig. 2 Effect of FXa and thrombin on LX2 hepatic stellate cell contractility assays at 6 h Collagen lattices with LX2 agonists (a - d) and bar graph
showing percentage gel contraction for FXa and/or thrombin. (e). LX2 cell collagen gels incubated with medium alone (a) with thrombin (10 nM)
(b & e) with FXa (0.5 U/ml) (c & e) and with FXa & thrombin (d & e). Relative contraction of the gels was expressed as a percentage of the surface area
contraction of each experimental gel in comparison to gels incubated with media and LX2 cells alone. Significance was denoted as *p < 0.05,
***p < 0.001 Abbreviations: FXa, Factor Xa. Black arrows indicate shrinkage of gel margin from wall of gel.
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this setting may also act as important mediators in hep-
atic fibrosis. We sought to examine the effects of FXa
and thrombin on HSCs in vitro, and to evaluate the
anti-fibrotic potential of both direct FXa and thrombin
inhibition using novel anticoagulants in a murine model
of fibrosis induced by TAA.
FXa and thrombin increase stellate cell contractility and
activation in vitro
The stellate cell is the principal cell type involved in
hepatic fibrogenesis and on stimulation contracts, a state
that is characterized by the increased expression of the
contractile filament protein, alpha smooth muscle actin
[30, 31]. We have demonstrated that culturing LX2 cells
with FXa or thrombin independently and in combination
results in stellate cell contraction. FXa concentration
used (0.5 U/ml or 174 nM) was within the plasma
physiological range (~ 150-200 nM). There is an upregu-
lation in procollagen, TGF-beta and αSMA gene expres-
sion only when FXa and Thrombin in combination were
given. These results are corroborated by our gel contrac-
tion assay, in which we were able to quantify a highly
significant increase in gel contraction when FXa and
thrombin were administered in combination compared
to alone. Both the upregulation of procollagen, TGF-
Beta, and αSMA and the contraction of LX2 cells in
Fig. 4 Mean percentage area of fibrosis, mean fibrosis visual scores, liver hydroxyproline and αSMA cells following 8 weeks of exposure with TAA.
Bar graphs showing (a) mean percentage area of fibrosis. Picro-Sirius red stained histological sections of liver were assessed under light microscopy for
fibrosis. The extent of hepatic fibrosis was assessed in field of view (n = 10) under a light microscope, using a semi-quantitative score [17] coupled with
digital image analyses (b) and mean visual fibrosis score agreed by two independent histopathologists using standardized protocols (c) liver
hydroxyproline content. Frozen liver samples (TAA; n = 13, TAA + RIV; n = 13; TAA + DAB; n = 11) were homogenized in water and hydrolysed in
HCl. Hydroxyproline was oxidized and reacted with DMAB to produce colour change which is directly proportional to Hydroxyproline concentration
and (d) mean number of αSMA cells following 8 weeks of TAA exposure. Histological sections were stained for αSMA as described under methods
and examined under a light microscope. Number of stellate cells stained positive for αSMA were counted per field of vision (n = 6), and an average
calculated, which represented the mean number of activated stellate cells. Data are mean +/− SEM unless otherwise stated. Abbreviations: DAB,
Dabigatran; RIV, Rivaroxaban; TAA, Thioacetamide; DMAB, 4-(dimethylamino) benzaldehyde. All sections were examined with a light microscope and
the number of stellate cells stained positive for αSMA were counted per field of vision at × 20 objective. Six fields per section were randomly chosen,
and an average calculated, which represented the mean number of activated stellate cells for each individual mouse per field
Dhar et al. BMC Gastroenterology  (2018) 18:60 Page 6 of 9
culture and gel contraction assays confirm FXa and
thrombin independently potentiate HSC activation and
in synergy this is significantly increased. A potential
mode of action for these proteins can be postulated.
Thrombin is known to be a mediator of stellate cell acti-
vation [18] and it is now established that the cellular ac-
tions of thrombin are in part mediated by PAR signaling
[14]. PAR receptors are a family of widely expressed
G-protein-coupled receptors, that transduce transmem-
brane signaling and four PARs have been identified [32].
PAR-1 and -3 are both preferentially activated by throm-
bin. PAR-4 has reduced affinity and PAR-2 is resistant to
thrombin activation. A substantial body of evidence
from in vivo and in vitro studies is now accumulating to
suggest PAR-1 activation leads to HSC activation [5, 33–
35]. Whilst thrombin PAR-1 mediated ligation results in
stellate cell activation, the mechanism by which fibro-
blasts are activated by FXa has been less well studied.
FXa, is a coagulation factor generated at the point of
convergence of the intrinsic and extrinsic coagulation
pathways and responsible for the conversion of pro-
thrombin to thrombin. Recent evidence suggests that
FXa activates PAR-1, in a similar fashion to thrombin,
but also has been demonstrated to activate PAR-2 [36,
37]. In pulmonary fibrosis which is a well-documented
paradigm for liver fibrosis, FXa mediated PAR1 activa-
tion has been demonstrated [20]. PAR-2 expression has
recently been demonstrated on both hepatic stellate cells
[1, 34, 35]: up-regulated in fibrotic livers [1]. PAR-2 defi-
ciency, using PAR-2 knockout mice, has been shown to
reduce CCL4 induced liver fibrosis [38]. FXa via the
added role of PAR-2 mediated activation could explain
the increased effect on stellate cell contraction and acti-
vation demonstrated with FXa or FXa with thrombin,
compared to thrombin alone. In vivo FXa is also central
in converting prothrombin to thrombin, with one mol-
ecule of FXa generating a ‘thrombin burst’ of over 1000
thrombin molecules [39]. Therefore FXa is pro-fibrotic
by two pathways. Firstly it drives thrombin production
and secondly, independent of its pro-coagulant activity,
we have demonstrated it potentiates activation of stellate
cells, but further experiments are required to confirm if
this is via PAR-1 and PAR-2 mediated mechanisms.
The efficacy of FXa and thrombin inhibition as antifibrotic
therapies in vivo
From the pathway described above, we can hypothesize
that targeting coagulation proteins earlier in the cascade
should enhance the anti-fibrotic effect rather than inhi-
biting thrombin alone. We sought to study this further
by using the oral anticoagulants, Rivaroxaban, a direct
FXa inhibitor, and Dabigatran, a direct thrombin antag-
onist in vivo using mice exposed to 8 weeks of TAA or-
ally to induce liver fibrosis. Preliminary experiments
were conducted to adjust the doses in animals to attain
the required level of anticoagulation. Tail bleeding was
done to ascertain coagulation time to give equivocal pro-
longation of coagulation time for the doses used. Doses
were increased until the same prolongation for both riv-
aroxaban and dabigatran was achieved. Using this model
we have demonstrated a significant reduction in mean
percentage area of fibrosis determined by digital image
analysis, mean fibrosis scores, αSMA expression and
hepatic hydroxyproline content in mice treated with
Rivaroxaban, at a dose of 40 mg/kg versus control mice.
In contrast, Dabigatran at a dose of 100 mg/kg did not
result in a significant reduction in these parameters with
the exception of hepatic hydroxyproline, versus control
animals and a significantly higher mean percentage area
of fibrosis and hepatic hydroxyproline content compared
to Rivaroxaban treated mice, despite an equivalent level
of anticoagulation. The concordance between our in
vitro and in vivo data highlights the particular import-
ance of the coagulation protein FXa, as well as thrombin
in hepatic fibrosis. In vivo the administration of the FXa
inhibitor, Rivaroxaban, not only inhibits FXa, but will
prevent the downstream production of the thrombin
‘burst’ [25]. Accordingly, the significant reduction in fi-
brosis and αSMA expression seen in mice exposed to
TAA and treated with Rivaroxaban, could be explained
by both the direct reduction in FXa mediated PAR1 and
PAR2 activation, as well as the indirect reduction in
thrombin mediated stellate cell activation via PDGF,
TGF-beta and PAR1 ligation. This would also explain
why direct thrombin inhibition with Dabigatran was less
effective anti-fibrotic intervention compared to FXa in-
hibition with Rivaroxaban, since inhibition of thrombin
alone would fail to block FXa PAR mediated activation
of stellate cells and fibrogenesis. Parallels can be drawn
with previous unpublished data from our group, in
which Ximelagatran, a thrombin antagonist that has
now been withdrawn from clinical use, was found to be
less effective than warfarin in reducing fibrosis in wild-
type C57BL/6 J mice, possibly suggesting that modula-
tion of factors II, VII, IX and X by warfarin provided
additional anti-fibrotic effects over direct thrombin (II)
blockade alone (Anstee and Thursz, un-published data).
Heparin will have a similar effect to FXa inhibitors due
to a similar mode of action. Therefore any potential ben-
efits demonstrated with Direct-acting Oral anticoagu-
lants could also be demonstrated with heparin, however
further studies are required.
Conclusions
In summary the results generated by this study further
support the role of coagulation proteins in the pathogen-
esis of hepatic fibrogenesis. We have demonstrated that
FXa and thrombin both independently and in synergy
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promote hepatic stellate cell activation and early inhib-
ition of coagulation using an FXa inhibitor significantly
reduced the rate of hepatic fibrosis and stellate cell ac-
tivity in a mouse model of liver fibrosis compared to dir-
ect thrombin inhibition. This effect is likely due to the
failure of direct thrombin inhibition to block PAR-me-
diated stellate cell activation by FXa, and highlights the
importance of inhibiting the coagulation cascade earlier
when planning anti-fibrotic therapies. A UK based phase
II study examining the effects of anticoagulation in liver
fibrosis in patients post liver transplant infected with
HCV is currently being undertaken to further evaluate
the anti-fibrotic potential of anticoagulation in liver dis-
ease (ISRCTN 12504151). In view of our findings and
recent trials demonstrating the safety of FXa inhibitors,
consideration should be given to trials using these new
agents as potential anti-fibrotics which, unlike warfarin,
do not require frequent monitoring.
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